The Arg16Gly and the Gln27Glu polymorphisms in the gene for the b 2 -adrenergic receptor (b 2 AR) have been linked to an increased risk for cardiovascular disease. The aim of the present study was to evaluate the significance of these haplotypes for development of myocardial infarction (MI) as well as other cardiovascular phenotypes. In a prospective study cohort (CAPPP), 522 hypertensive patients (174 MI and 348 matched controls) were analysed for the Arg16Gly and the Gln27Glu polymorphisms by dynamic allele-specific hybridisation. The haplotype could successfully be determined in 516 patients. Haplotype was not significantly associated with MI. Systolic blood pressure (SBP) was higher in patients with Arg16Gly þ Gln27Gln and lower in patients with Arg16Gly þ Gln27Glu as compared with the other haplotypes. Haplotype was not associated with body mass index, diastolic blood pressure, cholesterol, LDL, HDL triglycerides or a diagnosis of diabetes mellitus. The present study found no evidence that haplotype for the two most common polymorphisms in the b 2 AR are associated with development of MI in a Swedish hypertensive population, but haplotype may be associated with SBP.
1 Several polymorphisms have been described in the gene for the b 2 AR. The A46G and the C79G polymorphisms are common polymorphisms and both result in amino-acid substitutions of the b 2 ARs, Arg16Gly and Gln27Glu, respectively. The positions are located in the amino terminus of the receptor and seem to influence the degree of downregulation of the receptor, 2 which may affect vascular reactivity.
1 b 2 AR polymorphisms have been associated with increased risk for cardiovascular disease through intermediate end points such as body mass index (BMI), 3 hypertension, 3, 4 prevalence of diabetes mellitus type II. 4 Polymorphisms in the gene for the b 2 AR have also been reported to be associated with excess coronary events. 5 The results, however, are not consistent. 6 The primary aim of the present study was to evaluate the significance of haplotype of the two most common polymorphisms in the b 2 AR gene for development of myocardial infarction (MI) in a prospective hypertensive study cohort. A secondary aim was to investigate whether the haplotype was related to phenotype parameters linked to excess cardiovascular risks.
Materials and methods

Patients
Blood samples were collected from the patients after obtaining informed consent during the CAPtopril Prevention Project (CAPPP) 7 and stored at À701C. CAPPP was a large prospective morbidity and mortality study in hypertension. Patients who experienced the primary end point fatal or nonfatal MI during the study were matched to controls (matched for age, sex and smoking) without these cardiovascular end points. The study complies with the Declaration of Helsinki and was approved by the Ethics Committee of the University of Gothenburg. In all, 174 MI patients were available for analysis (ie these patients had blood samples stored to be genotyped) and 348 control patients were selected to achieve a 1:2 case-control study (74% men, 26% women, mean age (s.d.): 57 (7) years). Characteristics of the MI and the control hypertensive patients are presented in Table 1 .
DNA isolation and genotyping
Pure genomic DNA was isolated from frozen whole blood with the use of a commercial kit (Wizard 0 . The b 2 AR polymorphisms were genotyped using the dynamic specific hybridisation (DASH) method. 9 The following probes were used in the DASH analyses: ( 
Statistics
Statistical analyses were conducted using SPSS 12.0. The allelic frequency distribution was tested for Hardy-Weinberg equlibrium by the w 2 -test.
Fischer's exact test was used for association analysis of haplotypes and MI as well as diabetes mellitus. Phenotype parameters were compared using oneway ANOVA with Tukey's post hoc test. A twotailed P-value of less than 0.05 was considered significant. The data were expressed as mean (s.d.).
Results
Baseline characteristics for MI and control patients are presented in Table 1 . Age, sex, smoking status, systolic blood pressure (SBP), diastolic blood pressure (DBP), cholesterol and LDL did not differ between the two groups, whereas the MI patients were more likely to have diabetes mellitus and to have higher BMI, lower HDL and higher triglycerides (TG). The haplotype could successfully be determined in 516 patients. Haplotype was not significantly associated with MI (Table 2 ). SBP was higher in patients with Arg16Gly þ Gln27Gln and lower in patients with Arg16Gly þ Gln27Glu as compared with the other haplotypes ( Table 3 , P ¼ 0.028 (oneway ANOVA) and P ¼ 0.013 (Tukey's post hoc test)). Haplotype was not associated with diabetes mellitus, BMI, DBP, cholesterol, LDL, HDL or TG.
The allelic frequency distribution did not deviate from the Hardy-Weinberg equilibrium.
Discussion
The primary aim of the present study was to evaluate the significance of haplotype of the b 2 AR for development of MI in a prospective study cohort of low to intermediate risk hypertensive patients. who also did not find an association between the b 2 AR polymorphism and MI in a retrospective casecontrol study in Japanese.
Contrasting findings to ours have been reported by Heckbert et al
6 who found a lower risk of coronary events for Glu27 carriers compared with Gln27 homozygotes. Their association analysis, however, was based on the polymorphisms alone and not the haplotype. When performing the same type of analysis in the present study as that performed in the study by Heckbert et al, 6 no association between Glu27 carriers or Gln27 homozygotes and MI could be found. The Heckbert et al 6 study differs in several respects to the present one since they included coronary disease death in addition to MI in their analysis. Their cohort also had a different composition in that that their patients were older and normotensives as well as hypertensives.
Secondary aims of our study were to investigate to what extent the haplotype of b 2 AR is associated with phenotype parameters. SBP was higher in patients with Arg16Gly þ Gln27Gln and lower in patients with Arg16Gly þ Gln27Glu as compared with the other haplotypes. Heckbert et al 6 reported a lower risk of coronary events for Glu27 carriers than for Gln27 homozygotes. Their findings agree with the present one in that that the patients with higher SBP could be expected to be at increased risk for coronary events. Our cohort, however, may have been too young to exhibit effects on cardiovascular outcome. The finding is also in concordance with the finding of Cockcroft et al, 1 who reported a lower baseline blood flow and an attenuated increase in forearm blood flow in response to isoproterenol in subjects with Gln27.
The diverse findings mentioned above emphasise the difficulties of genetic association studies. Often results from previous studies are difficult to reproduce as pointed out by Ioannidis et al.
11 Differences in the findings may also be due to true differences in populations studied. The strength of the present study is that it represents a prospective study design with well-characterised patients and carefully validated end points.
In conclusion, the present study support the notion that haplotype for the polymorphisms Arg16Gly and Gln27Gly in the b 2 AR gene does not predict MI in Caucasian hypertensives, but may be associated with SBP. 
